Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel ...

President Trump had another medical exam on Tuesday, putting his health under renewed public scrutiny after he has worked to ...

Stanford Health Care started asking patients about new AI tools before they are implemented. Here's what patients are telling ...

Then why are so many optimistic scientists now losing heart? Because the nation’s research enterprise is shrinking.

For Wall Street, the political risk of investing in drug companies has been demoted in comparison to other concerns ...

Inside the longevity conference that brings together founders, investors, biohackers, and the generally death-averse to ...